Antiretroviral therapy and pre-exposure prophylaxis: combined impact on HIV transmission and drug resistance in South Africa.
暂无分享,去创建一个
Robert Glaubius | Anuj Mubayi | Gregory Hood | R. Glaubius | U. Abbas | J. Mellors | A. Mubayi | John W Mellors | Ume L Abbas | Gregory Hood
[1] Michael Rayment,et al. Prevention of HIV-1 infection with early antiretroviral therapy , 2012, Journal of Family Planning and Reproductive Health Care.
[2] D. Katzenstein,et al. Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa , 2010, AIDS (London).
[3] F. Dabis,et al. Derivation of parameters used in Spectrum for eligibility for antiretroviral therapy and survival on antiretroviral therapy , 2010, Sexually Transmitted Infections.
[4] M. Egger,et al. Outcomes of Antiretroviral Treatment Programs in Rural Southern Africa , 2012, Journal of acquired immune deficiency syndromes.
[5] Simon Wain-Hobson. Virus Dynamics: Mathematical Principles of Immunology and Virology , 2001, Nature Medicine.
[6] T. F. Rinke de Wit,et al. Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[7] O. Laeyendecker,et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. , 2005, The Journal of infectious diseases.
[8] David V Glidden,et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. , 2010, The New England journal of medicine.
[9] B. Branson,et al. Vital signs: HIV prevention through care and treatment--United States. , 2011, MMWR. Morbidity and mortality weekly report.
[10] D. Pillay,et al. The effect of transmitted HIV-1 drug resistance on pre-therapy viral load , 2010, AIDS.
[11] Sabine Yerly,et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. , 2009, The Lancet. Infectious diseases.
[12] F. Hecht,et al. Differential persistence of transmitted HIV-1 drug resistance mutation classes. , 2011, The Journal of infectious diseases.
[13] J. Margolick,et al. Human Immunodeficiency Virus Type 1 Population Genetics and Adaptation in Newly Infected Individuals , 2008, Journal of Virology.
[14] John T Brooks,et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. , 2012, The New England journal of medicine.
[15] James D. Campbell,et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. , 2012, The New England journal of medicine.
[16] P. Kaye. Infectious diseases of humans: Dynamics and control , 1993 .
[17] A. Wensing,et al. Evolutionary pathways of transmitted drug-resistant HIV-1. , 2011, The Journal of antimicrobial chemotherapy.
[18] S. Rosen,et al. Retention in HIV Care between Testing and Treatment in Sub-Saharan Africa: A Systematic Review , 2011, PLoS medicine.
[19] D. Pillay,et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis , 2012, The Lancet.
[20] Eduard Hofer,et al. Sensitivity analysis in the context of uncertainty analysis for computationally intensive models , 1999 .
[21] Ian Sanne,et al. The high cost of second-line antiretroviral therapy for HIV/AIDS in South Africa , 2010, AIDS.
[22] Katrien Fransen,et al. Preexposure prophylaxis for HIV infection among African women. , 2012, The New England journal of medicine.
[23] B. Stilwell,et al. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 revision. , 2006 .
[24] S. Lawn,et al. Changes in Programmatic Outcomes During 7 Years of Scale-up at a Community-Based Antiretroviral Treatment Service in South Africa , 2011, Journal of acquired immune deficiency syndromes.
[25] M. Chopra,et al. The failure of routine rapid HIV testing: a case study of improving low sensitivity in the field , 2010, BMC health services research.
[26] B. Chi,et al. Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in southern Africa , 2011, AIDS.
[27] A. Wensing,et al. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. , 2010, The Lancet. Infectious diseases.
[28] C. Deal,et al. O11.1 Herpes Simplex Virus (HSV) Infection in the VOICE (MTN 003) Study: Pre-Exposure Prophylaxis (PrEP) For HIV with Daily Use of Oral Tenofovir, Oral Tenofovir-Emtricitabine, or Vaginal Tenofovir Gel , 2013, Sexually Transmitted Infections.
[29] F. Wit,et al. Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. , 2012, The Lancet. Infectious diseases.
[30] T. Hallett,et al. A Decline in New HIV Infections in South Africa: Estimating HIV Incidence from Three National HIV Surveys in 2002, 2005 and 2008 , 2010, PloS one.
[31] J. Inciardi,et al. Mechanisms of prescription drug diversion among drug-involved club- and street-based populations. , 2007, Pain medicine.
[32] Roy M. Anderson,et al. Potential Impact of Antiretroviral Chemoprophylaxis on HIV-1 Transmission in Resource-Limited Settings , 2007, PloS one.
[33] E Windisch,et al. [South Africa]. , 1976, Osterreichische Krankenpflegezeitschrift.
[34] S. Vermund,et al. Impact of small reductions in plasma HIV RNA levels on the risk of heterosexual transmission and disease progression , 2008, AIDS.
[35] Kishor Mandaliya,et al. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. , 2011, The Lancet. Infectious diseases.
[36] M. Wainberg,et al. Transmission dynamics of the M184V drug resistance mutation in primary HIV infection. , 2011, The Journal of antimicrobial chemotherapy.
[37] R Hoh,et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. , 2001, The New England journal of medicine.
[38] Christopher Dye,et al. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model , 2009, The Lancet.
[39] N. Parkin,et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy , 2009, AIDS.
[40] M. Zwahlen,et al. Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies , 2008, Sexually Transmitted Infections.
[41] Organización Mundial de la Salud,et al. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress report 2009 , 2009 .
[42] Jacques Izopet,et al. Changes in Human Immunodeficiency Virus Type 1 Populations after Treatment Interruption in Patients Failing Antiretroviral Therapy , 2001, Journal of Virology.